Loading
institutionsInstitution
European Hematology Association
Europe's haematology society, whose June congress is the second global venue for blood cancer trials and whose guidelines and curriculum shape European haematology.
Also called: EHA
Overview
Founded in 1992, EHA represents haematologists across Europe and beyond, with its annual congress each June attracting more than 15,000 delegates and presenting the year's leukaemia, lymphoma and myeloma trial data, second only to ASH. It publishes HemaSphere, issues clinical guidelines and the European Hematology Curriculum, runs research fellowships and the EHA-ASH Translational Research Training in Hematology programme, and advocates in Brussels on medicines regulation, rare diseases and research funding. Its Scientific Working Groups on CLL, myeloma, AML, MDS and lymphoma link the national cooperative groups such as HOVON, GIMEMA and the German study groups.
Location
The Hague, NL
Type
consortium
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#224 · 26 points (0 Newsweek + 0 NCI + 26 from 13 linked objects) · ranking
- EHA Congress (June)
- HemaSphere
- Clinical guidelines and European Hematology Curriculum
- Fellowships and EHA-ASH training
Brian Huntly
President Elect
Acute myeloid leukaemiaLeukaemia stem cellsEpigenetics
Cambridge haematologist and EHA President Elect whose laboratory studies how epigenetic regulators drive leukaemia and how they can be targeted.
Konstanze Döhner
President
Acute myeloid leukaemiaMolecular genetics of leukaemiaClinical haematology
Ulm haematologist and President of the European Hematology Association, a leading figure in the molecular genetics and risk classification of acute myeloid leukaemia.
Michael Hallek
Director, Department I of Internal Medicine, University Hospital Cologne; Head, German CLL Study Group
Chronic lymphocytic leukaemiaChemoimmunotherapyTargeted therapy trials
Leads the German CLL Study Group, whose trials (CLL8, CLL14, CLL13) set global standards for CLL treatment.
Lars Bullinger
Director, Department of Hematology, Oncology and Tumor Immunology, Charité
Acute myeloid leukaemiaLeukaemia genomicsHaematology
Lars Bullinger is a haematologist and AML genomics researcher leading Charité's haematology department.
Similar pages
- PersonNicolaas P.M. Schaap
Shares Haematologica, HOVON, Acute myeloid leukaemia, Multiple myeloma.
- CollectionLeukemia & Lymphoma Society (LLS)
Shares American Society of Hematology, Chronic lymphocytic leukaemia, Hodgkin lymphoma, Acute lymphoblastic leukaemia.
- PersonAntonio Cuneo
Shares Haematologica, GIMEMA, Chronic lymphocytic leukaemia.
- IdeaPlan the second CAR-T target before the first one is lost
Shares Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, CAR-T cell therapy, Acute lymphoblastic leukaemia.
- InstitutionIRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola
Shares Bispecific antibodies, Hodgkin lymphoma, CAR-T cell therapy, Acute myeloid leukaemia.
- PersonMarco Vignetti
Shares GIMEMA, Acute lymphoblastic leukaemia, Acute myeloid leukaemia.
- PersonJürgen Kuball
Shares Haematologica, Acute myeloid leukaemia, Multiple myeloma.
- PersonSirpa Leppä
Shares Haematologica, Hodgkin lymphoma, Diffuse large B-cell lymphoma.